Delving into the Latest Updates on Magnesium Sulfate Hydrate/Glucose with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Magnesium Sulfate Hydrate・Glucose, Magsent, マグセント

Target-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

EclampsiaObstetric Labor, Premature

Inactive Indication-

Originator Organization

ASKA Pharmaceutical Co., Ltd.

Active Organization

TOA Pharmaceuticals Co., Ltd.

ASKA Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (23 Jan 2006),

Obstetric Labor, Premature

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC6H14O7

InChIKeyOSNSWKAZFASRNG-UHFFFAOYSA-N

CAS Registry1258214-35-5

View All Structures (2)

Sequence Code 67268

The sequence is quoted from: *****

The purpose of study is to assess the effectiveness of nebulized magnesium sulphate in children presenting with acute asthma.Study perfoma consists of demographic variables,exclusion criteria and pediatric asthma score that includes respiratory rate,SPO2 at room air(requirement of oxygen),auscultatory findings in chest,dysnea and retractions.

Start Date01 Oct 2019

Sponsor / Collaborator

King Edward Medical University

[+1]

NCT04328636

/ CompletedPhase 1/2IIT

Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn

The aim of this pilot randomized controlled blinded study is to evaluate the feasibility of using nebulized magnesium sulfate in the treatment of PPHN.

Start Date01 Nov 2017

Sponsor / Collaborator

Sohag University

100 Clinical Results associated with Magnesium Sulfate Hydrate/Glucose

Login to view more data

100 Translational Medicine associated with Magnesium Sulfate Hydrate/Glucose

Login to view more data

100 Patents (Medical) associated with Magnesium Sulfate Hydrate/Glucose

Login to view more data

1

Literatures (Medical) associated with Magnesium Sulfate Hydrate/Glucose

01 Sep 2022·Biological and Pharmaceutical Bulletin

Classification of Skin Injury Risk Caused by Extravasation of Electrolyte Solutions or Infusions in a Rat Model

Article

Author: Shibata, Yuuka ; Uno, Hiromi ; Yokooji, Tomoharu ; Matsuo, Hiroaki ; Hide, Michihiro ; Tanaka, Maiko ; Taogoshi, Takanori

Cytotoxic agents are classified according to the severity of skin injury after extravasation. However, injuries caused by extravasation of noncytotoxic agents have not been sufficiently investigated, although the risk of extravasation is mentioned in medical safety information published by the Japan Council for Quality Health Care. Therefore, in this study, we focused on noncytotoxic electrolyte solutions and infusions and evaluated skin injuries during leakage using extravasation model rats. Rats were anesthetized and intradermally injected with 100 µL of an electrolyte solution or infusion. Injection lesions were macroscopically and histopathologically evaluated for extravasation injuries. Each electrolyte solution and infusion were classified into three categories (vesicants, irritants, and non-tissue-damaging agents) depending on the degree of skin injury. Similar to saline, 0.3% potassium chloride and 0.6% magnesium sulfate showed almost no injury, and 3% sodium chloride and BFLUID^® caused erythema and induration. Erythema, induration, and ulceration were observed with the following: 10% sodium chloride, 2% calcium chloride, 8.5% calcium gluconate, 12.3% magnesium sulfate, MAGSENT^®, FESIN^®, and Intralipos^®. The duration of damage with these agents was markedly prolonged. Electrolyte solutions and infusions can be classified into vesicants (10% sodium chloride, 2% calcium chloride, 8.5% calcium gluconate, 12.3% magnesium sulfate, MAGSENT^®, FESIN^®, and Intralipos^®), irritants (3% sodium chloride and BFLUID^®), and non-tissue-damaging agents (0.3% potassium chloride and 0.6% magnesium sulfate) according to their composition. The characteristic symptoms and severity of each drug extravasation revealed in this study will provide basic information for preparation of guidelines for treatment of extravasation.

100 Deals associated with Magnesium Sulfate Hydrate/Glucose

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Eclampsia	JP	ASKA Pharmaceutical Co., Ltd.	25 Mar 2013
Eclampsia	JP	TOA Pharmaceuticals Co., Ltd.	25 Mar 2013
Obstetric Labor, Premature	JP	ASKA Pharmaceutical Co., Ltd.	23 Jan 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04328636 (Pubmed \| Indian J Pediatr)	Phase 1/2	Persistent Fetal Circulation Syndrome	28	Nebulized Magnesium Sulfate	xcjllnswdw(ceghvjgiwe) = ngjvjofuje yhygabqxyi (rgcoyfbkvc )	-	08 Jan 2021
				IV Magnesium	lzyqxwsiyi(uihjcqcxld) = cldbamldof blexayvgsz (yyrjasqnzb )
NCT01515995 (CTgov)	Phase 4	Asthma	50	Nebulized magnesium sulfate (Magnesium Sulfate Group)	bejxgtopmm(clqfitfyfw) = ttikpvkjyc eteecfnvzh (zpogdrijdf, zxonggkswg - lmeevhomtx) View more	-	21 Feb 2019
				Nebulized magnesium sulfate (Normal Saline Group)	bejxgtopmm(clqfitfyfw) = uaaxpyeobi eteecfnvzh (zpogdrijdf, mmaczyeyie - aquyvkothw) View more
Pubmed \| J Emerg Med	Not Applicable	Asthma	-	Nebulized magnesium sulfate plus albuterol	(notbpenoqt) = wnxhhveuxg semryremdt (ifbjqbgnvh )	Positive	01 Jul 2004
				Nebulized albuterol plus saline	(notbpenoqt) = chcxxjsrnn semryremdt (ifbjqbgnvh )